Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors

Completed · Phase 1/Phase 2

Conditions studied: Non-Small Cell Lung Cancer, Prostate Cancer, Pancreatic Cancer

In brief

The purpose of this study is to determine if TH-302, in combination with A) Gemcitabine, or B) Docetaxel or C) Pemetrexed methotrexate, are safe and effective in the treatment of Pancreatic Cancer, Castrate-resistant Prostate Cancer, and Non-small Cell Lung Cancer, respectively.

Key facts

Study ID

NCT00743379

Run by

Threshold Pharmaceuticals

People needed

71

Starts

2008-08-01

Expected to finish

2014-03-01

Last updated by the study team

2015-05-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Mayo Clinic Cancer Center — Scottsdale, Arizona, United States
• Premiere Oncology of Arizona — Scottsdale, Arizona, United States
• Indiana University Cancer Center — Indianapolis, Indiana, United States
• LSU Health Sciences Center — Shreveport, Louisiana, United States
• Karmanos Cancer Institute — Detroit, Michigan, United States
• Mayo Clinic — Rochester, Minnesota, United States
• Duke University Medical Center — Durham, North Carolina, United States
• Sarah Cannon Research Institute — Nashville, Tennessee, United States
• UT Health Science Center — San Antonio, Texas, United States
• Northwest Medical Specialties — Tacoma, Washington, United States
• University of Wisconsin — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.